Skip to main content

Public Comment & Letters of Support

Thumbnail image representing the cover of a letter of support

Letter of Support

Providing Realistic Opportunity to Equal and Comparable Treatment (“PROTECT Rare”) Act

The bill will build on existing criteria for medically necessary care so that Medicare and Medicaid will be able to consider clinical guidelines and peer-reviewed literature to assess coverage of rare disease treatments. Importantly, the bill does not provide ‘special treatment’ for rare diseases; rather, it levels the playing field for access to those living with more common conditions.

Thumbnail image representing the cover of a letter of support

Letter of Support

Minnesota State Legislation SF 2744 that appoints the Council to the advisory committee of the Prescription Drug Affordability Board

The development and availability of transformative treatments for rare diseases poses both an incredible opportunity and an enormous challenge for the state of Minnesota. RDAC inclusion on the PDAB ensures that rare disease drug development and research is not restricted nor held to the same standards as common diseases while at the same time sustainable reimbursement models that balance value and cost are considered.

Thumbnail image representing the cover of a public comment paper

Public Comment

Accelerated Approval Drugs contained in Oregon’s 1115(a) Demonstration Waiver

MNRDAC believes that the restrictions on drugs approved through the FDA’s Accelerated Approval Pathway in this proposal will significantly impede access to medically necessary treatments for rare disease patients who are enrolled in Oregon’s Medicaid program and exacerbate inequities that already exist for the rare disease community related to the availability of treatments.

Thumbnail image representing the cover of a letter of support

Letter of Support

David J. Tomassoni Center for Innovation in ALS Research and Care across Minnesota

The Tomassoni Center will provide a cost-effective mechanism to avoid administrative replication and leverage the strengths of each institution/investigator on a statewide level, while also enabling the exponential advancement of both research and clinical care that inevitably arises from collaboration and sharing of ideas.